351003-62-8Relevant articles and documents
PHOSPHODIESTERASE INHIBITORS AND USE
-
Paragraph 0112; 0181, (2021/04/02)
The invention provides compounds that may inhibits to ENPP1, and are accordingly useful for treatment disorders related to ENPP1. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent disorders related to ENPP1.
ARYL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR
-
Page/Page column 14, (2008/12/08)
In one embodiment, compounds of the following structure are described, wherein R1 to R7 are described herein. Also provided are methods for preparing these compounds and methods of contraception; treating or preventing fibroids; trea
SUBSTITUTED BIPHENYL DERIVATIVE
-
Page/Page column 148, (2010/11/27)
The present invention relates to a biaryl derivative or a pharmacologically acceptable salt thereof having an excellent collagen-synthesis inhibition activity. A biaryl derivative having a structure represented by the following General Formula (I) or a pharmacologically acceptable salt thereof: wherein R1 represents a C6-C10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C1-C6 alkyl)amino group, a di-(C1-C6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C1-C6 alkyl group, and so on; L represents a sulfonyl group, an aminosulfonyl group, or a sulfonylamino group, and so on; R2 represents a hydrogen atom, and so on; A represents a group defined by formula (II), (III), or (IV); R3 represents a C1-C6 alkyl group, and so on; and R4 represents a C1-C6 alkyl group, and so on.
Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping
Richardson, Christine M.,Nunns, Claire L.,Williamson, Douglas S.,Parratt, Martin J.,Dokurno, Pawel,Howes, Rob,Borgognoni, Jenifer,Drysdale, Martin J.,Finch, Harry,Hubbard, Roderick E.,Jackson, Philip S.,Kierstan, Peter,Lentzen, Georg,Moore, Jonathan D.,Murray, James B.,Simmonite, Heather,Surgenor, Allan E.,Torrance, Christopher J.
, p. 3880 - 3885 (2008/02/08)
Virtual screening against a pCDK2/cyclin A crystal structure led to the identification of a potent and novel CDK2 inhibitor, which exhibited an unusual mode of interaction with the kinase binding motif. With the aid of X-ray crystallography and modelling,